Product Description

Remifemin tablet is supported by over *0 years of documented experience with isopropanol extract of Cimicifuga racemosa (iCR). Cimicifuga racemosa extracts are an important treatment option for menopausal symptoms worldwide. The first medicinal product from Cimicifuga has been available in the form of isopropanol extract iCR since ***6 (Remifemin Germany). During the *0s to *0s clinical studies on Cimicifuga were observational studies, but then in the *0s, controlled studies began to be published. The rst placebo-controlled study emerged in ***6. From ***0 to ***5, a total of *8 clinical studies in Europe, America, and Asia were published on the efficacy of Cimicifuga. In these studies, *1,**3 patients received a Cimicifuga-based medicinal product, *3% thereof iCR.A meta-analysis of all nine placebo-controlled studies published until ***3 confirmed the reliable efficacy of Cimicifuga-based medicinal products for menopausal symptoms.